175 related articles for article (PubMed ID: 7564153)
1. [Long-term infusion of L-asparaginase--an alternative to intramuscular injection?].
Rodriguez T; Baumgarten E; Fengler R; Soumpasis D; Henze G
Klin Padiatr; 1995; 207(4):207-10. PubMed ID: 7564153
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
4. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
Albertsen BK; Schrøder H; Jakobsen P; Avramis VI; Müller HJ; Schmiegelow K; Carlsen NT
Med Pediatr Oncol; 2002 May; 38(5):310-6. PubMed ID: 11979454
[TBL] [Abstract][Full Text] [Related]
5. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
7. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
Domenech C; Thomas X; Chabaud S; Baruchel A; Gueyffier F; Mazingue F; Auvrignon A; Corm S; Dombret H; Chevallier P; Galambrun C; Huguet F; Legrand F; Mechinaud F; Vey N; Philip I; Liens D; Godfrin Y; Rigal D; Bertrand Y
Br J Haematol; 2011 Apr; 153(1):58-65. PubMed ID: 21332712
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase].
Wu ZL; Chen FX; Ye TZ; Lai YH; Cui YQ; Zou YW; Lu CY; Lan SL; Zhong GY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):14-6. PubMed ID: 16732932
[TBL] [Abstract][Full Text] [Related]
9. [Allergic reactions in treatment with L-asparaginase. Significance of specific IgE antibodies].
Körholz D; Wahn U; Jürgens H; Wahn V
Monatsschr Kinderheilkd; 1990 Jan; 138(1):23-5. PubMed ID: 2314401
[TBL] [Abstract][Full Text] [Related]
10. [Clinical experiences with adrenaline as therapy and prevention of E. coli-L-asparaginase-induced anaphylaxis].
Schwinger W; Urban C; Lackner H
Klin Padiatr; 1992; 204(4):274-6. PubMed ID: 1518264
[TBL] [Abstract][Full Text] [Related]
11. Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic.
Morimoto A; Imamura T; Ishii R; Nakabayashi Y; Nakatani T; Sakagami J; Yamagami T
Cancer; 2008 Sep; 113(6):1362-9. PubMed ID: 18661511
[TBL] [Abstract][Full Text] [Related]
12. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
[TBL] [Abstract][Full Text] [Related]
13. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Larson RA; Fretzin MH; Dodge RK; Schiffer CA
Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
16. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
[TBL] [Abstract][Full Text] [Related]
17. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Wacker P; Land VJ; Camitta BM; Kurtzberg J; Pullen J; Harris MB; Shuster JJ;
J Pediatr Hematol Oncol; 2007 Sep; 29(9):627-32. PubMed ID: 17805038
[TBL] [Abstract][Full Text] [Related]
18. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
Sikorska-Fic B; Makowska K; Rokicka-Milewska R
Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
[TBL] [Abstract][Full Text] [Related]
19. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
[TBL] [Abstract][Full Text] [Related]
20. Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia.
Cetin M; Yetgin S; Kara A; Tuncer AM; Günay M; Gümrük F; Gürgey A
J Med; 1994; 25(3-4):219-29. PubMed ID: 7996065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]